Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer’s disease
Abstract Background The FDA have recently published draft guidance for the development of treatments for early Alzheimer’s disease. Key features of this guidance are the advocacy of sensitive cognitive measures and a taxonomy of disease severity. Whilst desirable patterns of cognitive-functional imp...
Main Author: | John E. Harrison |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-06-01
|
Series: | Alzheimer’s Research & Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13195-018-0386-7 |
Similar Items
-
Cognitive and Neuropsychiatric Symptom Differences in Early Stages of Alzheimer’s Disease: Kuopio ALSOVA Study
by: Ilona Hallikainen, et al.
Published: (2012-05-01) -
Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer's disease in a memory clinic sample
by: Marie Eckerström, et al.
Published: (2017-01-01) -
A new Brief computerized cognitive screening battery (CompCogs) for early diagnosis of Alzheimer's disease
by: Helenice Charchat Fichman, et al. -
Memory Alteration Test to Detect Amnestic Mild Cognitive Impairment and Early Alzheimer’s Dementia in Population with Low Educational Level
by: Nilton Custodio, et al.
Published: (2017-08-01) -
Slowing of EEG background activity in Parkinson´s and Alzheimer´s Disease with early cognitive dysfunction
by: Nina eBenz, et al.
Published: (2014-11-01)